Search / Trial NCT06229353

Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department

Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Jan 26, 2024

Trial Information

Current as of October 03, 2024

Recruiting

Keywords

Gardasil 9 Hpv

Description

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * aged 18-45 years old
  • * in good functional capacity, as determined by the ED-attending clinician
  • * no known infection with HPV high risk strain types 6, 11, 16 and 18.
  • Exclusion Criteria:
  • * will not receive vaccine if participants lack mental clarity and if running a fever or in some pain.
  • * Patients aged \<18 or \> 45 years of age.
  • * Female patients with abnormal HPV results (including those with the high-risk HPV strain types 6, 11, 16, and 18) as determined by a previous PAP smear test or HPV test.
  • * Female patients who are known to be pregnant.
  • * Male patients with known cases of HPV-associated infections will also be excluded from the study

About Sponsor

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Birmingham, Alabama, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0